<DOC>
	<DOCNO>NCT00527371</DOCNO>
	<brief_summary>In patient enlarged prostate ( benign prostatic hyperplasia ) , treatment use photoselective vaporization prostate ( PVP 120 Watt ) effective cost-effective standard treatment transurethral resection prostate ( TURP ) ? A higher-power ( 120W ) laser system recently approve Health Canada treatment enlarge prostate . This system , use laser energy vaporize prostate tissue , compare current standard treatment transurethral resection prostate . This new generation laser may offer efficient removal prostate tissue few complication may result clinical economic benefit compare standard treatment . However , study compare 120W laser standard transurethral resection prostate . This study provide currently unavailable information clinician decision maker .</brief_summary>
	<brief_title>PVP Compared TURP Treatment Benign Hyperplasia Prostate</brief_title>
	<detailed_description>Following review treatment benign prostatic hyperplasia ( BPH ) Medical Advisory Secretariat ( MAS ) Ontario Ministry Health Long-Term Care ( MOHLTC ) , Ontario Health Technology Advisory Committee ( OHTAC ) recommend `` registry study conduct establish long term effectiveness complication rate PVP give likelihood increase diffusion technology '' . Since , Medical Devices Bureau Therapeutic Products Directorate , Health Canada , license April 30 , 2007 , 120W-KTP laser system ( Greenlight HPS ( TM ) ) sale Canada . As several new 120W system operate Ontario coming month , urgent need evaluate effectiveness , cost-effectiveness durability 120W PVP compare conventional TURP treatment patient BPH .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>Male age 40 Diagnosed symptomatic/obstructive symptom secondary BPH require surgical intervention determine urologist Experienced low urinary tract symptom ( LUTS ) secondary BPH &gt; 3 month duration IPSS value &gt; 12 Peak urinary flow &lt; 15mL/sec voided volume ( minimum 150 ml ) Prostate size , measure transrectal ultrasonography ( TRUS ) , less 100cc volume American Society Anesthesiology ( ASA ) classification physical status , class 13 Able read , understand , sign Informed Consent Willing able comply followup requirement include multiple followup visit Transvesically measure postvoid residual volume &gt; 400 mL Currently urinary retention Chronic urinary retention Medications impair bladder contractibility Uncorrectable bleeding disorder long term anticoagulation stop Recent myocardial infarction coronary artery stent placement Any follow disease appear involve bladder : myasthenia gravis , diabetes neuropathy , multiple sclerosis , spinal cord injury Parkinson disease Any patient idiopathic atonic bladder Major pelvic fracture involve damage external urinary sphincter Recently complete definitive radiation therapy prostate cancer Active localize systemic infection ; include active urinary tract infection Active cystolithiasis , urethral stricture , bladder neck contracture , acute prostatitis affect bladder function If patient 's PSA value &gt; PSA ageadjusted normal value , patient need negative biopsy participate study Confirmed malignancy prostate Bladder cancer treat transurethral resection bladder cancer ( TURBT ) within 12 month patient treat Bacillius CalmetteGuerin ( BCG ) Bilateral hydronephrosis renal ultrasound Urethral strictures residual volume &gt; 400 ml Immunocompromised Previous TURP</criteria>
	<gender>Male</gender>
	<minimum_age>41 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Benign hyperplasia prostate</keyword>
</DOC>